Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-alpha therapy for melanoma.

R Russell-Jones1

  • 1Skin Tumour Unit, St John's Institute of Dermatology, St Thomas' Hospital, London, UK.

Clinical and Experimental Dermatology
|February 15, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A brighter future for melanoma.

The British journal of dermatology·2019
Same author

The value of sentinel lymph node biopsy in Merkel cell carcinoma.

The British journal of dermatology·2016
Same author

When will selective lymphadenectomy become standard of care in melanoma?

International journal of clinical practice·2012
Same author

Predictors of patient satisfaction with initial diagnosis and management of malignant melanoma.

Clinical and experimental dermatology·2009
Same author

Bexarotene therapy for mycosis fungoides and Sézary syndrome.

The British journal of dermatology·2009
Same author

Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up.

The British journal of dermatology·2009
Same journal

Real-World Outcomes of Stapokibart-Based Combination Therapy for Bullous Pemphigoid: A Single-Center Retrospective Cohort.

Clinical and experimental dermatology·2026
Same journal

A second case of recessive mosaicism in ABCA12 causing a congenital unilateral epidermal nevus.

Clinical and experimental dermatology·2026
Same journal

Dermatopathology.

Clinical and experimental dermatology·2026
Same journal

Persistent Bilateral Palmar Hyperkeratotic Papules in an Adolescent Male.

Clinical and experimental dermatology·2026
Same journal

Shuddering Attacks in an Infant Treated with Atenolol for Infantile Hemangioma: A Previously Unreported Adverse Effect.

Clinical and experimental dermatology·2026
Same journal

Male genital fixed drug eruption: a systematic review.

Clinical and experimental dermatology·2026
See all related articles

Interferon (IFN)-alpha therapy shows therapeutic benefit for malignant melanoma patients. High-dose regimens may improve overall survival, while low-dose focuses on disease-free survival in adjuvant therapy.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Surgery is curative for early-stage malignant melanoma, but its effectiveness decreases with disease progression.
  • Adjuvant therapies are crucial for improving outcomes in advanced melanoma.
  • Interferon (IFN)-alpha is the only immunotherapy demonstrating significant benefit in randomized controlled trials for melanoma.

Purpose of the Study:

  • To review published data on Interferon (IFN)-alpha therapy in intermediate and high-risk melanoma.
  • To explore future management strategies for malignant melanoma.

Main Methods:

  • Review of published randomized controlled studies on Interferon (IFN)-alpha therapy.
  • Analysis of data differentiating low-dose and high-dose Interferon (IFN)-alpha regimens.

Main Results:

Related Experiment Videos

  • Low-dose Interferon (IFN)-alpha primarily impacts disease-free survival.
  • High-dose Interferon (IFN)-alpha regimens show potential for improving overall survival.

Conclusions:

  • Interferon (IFN)-alpha is a valuable adjuvant therapy for malignant melanoma.
  • Dose selection of Interferon (IFN)-alpha is critical for optimizing patient outcomes.
  • Further research is needed to refine management strategies for advanced melanoma.